Mat D. Davis

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

Karen E. Anderson, David Stamler, Mat D. Davis et al. · The Lancet Psychiatry · 2017 · 335 citations

Medicine, Neurology, Pharmacotherapy +9

Randomized controlled trial of deutetrabenazine for tardive dyskinesia

Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser et al. · Neurology · 2017 · 328 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline

P. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman et al. · Neurology · 2012 · 228 citations · Full text

Medicine, Neurology, Nuclear Medicine +17

Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

Reisa A. Sperling, Keith A. Johnson, P. Murali Doraiswamy et al. · Neurobiology of Aging · 2012 · 127 citations

Life Sciences, Neurology, Neuroscience +17

991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY

Mark Sulkowski, E. Läwitz, M. Shiffman et al. · Journal of Hepatology · 2008 · 47 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10